Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The 5th How to Diagnose and Treat: Acute Leukemias meeting of the European School of Hematology (ESH AL) took place on February 27 – March 1, 2026, in Mandelieu-La Napoule, France. This meeting addressed the latest best practices in the diagnosis and clinical management of acute leukemias through the presentation and discussion of real clinical cases.
View all videos

ESH AL 2026

The 5th How to Diagnose and Treat Acute Leukemias meeting
27 Feb–01 March 2026 | Mandelieu-La Napoule, France

ESH AL 2026

The 5th How to Diagnose and Treat Acute Leukemias meeting
27 Feb–01 March 2026 | Mandelieu-La Napoule, France
The 5th How to Diagnose and Treat: Acute Leukemias meeting of the European School of Hematology (ESH AL) took place on February 27 – March 1, 2026, in Mandelieu-La Napoule, France. This meeting addressed the latest best practices in the diagnosis and clinical management of acute leukemias through the presentation and discussion of real clinical cases.
View all videos

Latest videos

View all videos
4:48
Blinatumomab, inotuzumab & venetoclax in older patients with ALL: practical considerations
Marlise Luskin • 27 Feb 2026
1:38
MRD testing in ALL: advice for community physicians who may not have direct access to technologies
Wendy Stock • 28 Feb 2026
1:36
Treatment approaches for patients with IDH1-mutated AML & practical considerations
Thomas Cluzeau • 28 Feb 2026
1:44
The growing armamentarium of agents for older adults with ALL
Marlise Luskin • 27 Feb 2026

AML

View all
1:36
Treatment approaches for patients with IDH1-mutated AML & practical considerations
Thomas Cluzeau • 28 Feb 2026
7:48
MRD as a surrogate endpoint in AML: challenges, ongoing studies, and the need to standardize assays
Harry Erba • 28 Feb 2026
1:37
Why TP53-mutated AML is so therapeutically challenging: an insight into disease biology
Thomas Cluzeau • 27 Feb 2026
1:04
TP53-mutated AML: clinical outcomes with azacitidine-based therapy
Thomas Cluzeau • 27 Feb 2026

ALL

View all
4:48
Blinatumomab, inotuzumab & venetoclax in older patients with ALL: practical considerations
Marlise Luskin • 27 Feb 2026
1:38
MRD testing in ALL: advice for community physicians who may not have direct access to technologies
Wendy Stock • 28 Feb 2026
1:44
The growing armamentarium of agents for older adults with ALL
Marlise Luskin • 27 Feb 2026
1:55
Significant advances made in Ph+ ALL: TKIs, immunotherapy & more
Josep-Maria Ribera • 27 Feb 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals